ÐÇ¿Õ´«Ã½

Skip to main content

Dozens of firms to make cheap version of Merck COVID-19 pill for poorer nations

Share
BRUSSELS -

Nearly 30 generic drugmakers in Asia, Africa and the Middle East will make cheap versions of Merck & Co's COVID-19 pill, under a landmark UN-backed deal to give poorer nations wider access to a drug seen as a weapon in fighting the pandemic.

Merck's early greenlight to production of its anti-viral pill molnupiravir by other companies during the pandemic is a rare example in the pharmaceutical sector, which usually protects its patented treatments for longer periods.

However, there are questions about molnupiravir which has shown low efficacy in trials and has raised concerns for side-effects, and lengthy procedures for appovals may delay supplies in many poorer nations for months.

Under the deal, negotiated by the UN-backed Medicines Patent Pool (MPP) with Merck, the U.S. company will not receive royalties for the sale of the low-cost version of the pill while the pandemic continues.

The MPP said the deal stipulated the pill would be distributed to 105 less-developed nations.

A molnupiravir course of 40 pills for five days is expected to cost about US$20 in poorer nations, an MPP official involved in the talks with drugmakers told Reuters, citing initial estimates from drugmakers, which are subject to change.

That is far below the $700 per course the United States agreed to pay for an initial delivery of 1.7 million courses, but twice as high as first estimated by the World Health Organization (WHO)-backed program to procure COVID-19 drugs and vaccines for the world.

The new agreement allows 27 generic drugmakers from India, China and other countries in Africa, Asia and the Middle East to produce ingredients and the finished drug.

An MPP spokesperson said deliveries from some firms covered by the deal could start as early as February. However, that will be subject to regulatory approval.

While molnupiravir is in use in the United States after approval in December, some other Western countries have canceled or are reconsidering orders after the drug showed low efficacy in trials.

Molnupiravir has also not been approved by the World Health Organization, which makes its sale at the moment not possible in most developing countries with limited regulatory resources for national authorisations.

The drug can already be sold in India, after it received emergency approval by the national regulator, but it is not currently recommended for use because of safety risks.

NO ROYALTIES, FOR NOW

The developers of molnupiravir, which alongside Merck are U.S. firm Ridgeback Biotherapeutics and Emory University, will not receive royalties for the sale of the low-cost versions made by generic drugmakers while COVID-19 remains classified as a Public Health Emergency of International Concern by the WHO.

Bangladesh's Beximco Pharmaceuticals, India's Natco Pharma, South Africa's Aspen Pharmacare Holdings and China's Fosun Pharma are among generics firms that will produce the finished product.

Other companies, including India's Dr Reddy's Laboratories , had struck earlier deals with Merck for the production of molnupiravir. Dr Reddy's will sell molnupiravir at 1,400 rupees ($18.8) per course.

The MPP spokesperson said there was no firm estimate yet of the likely output from generics makers covered by the deal, but that poorer nations' demand was expected to be largely covered.

The MPP works to increase access to life-saving medicines for poorer countries. It also has an agreement with Pfizer for the sub-licensing of its COVID-19 pill paxlovid to generics drugmakers.

CTVNews.ca ÐÇ¿Õ´«Ã½

The province's public security minister said he was "shocked" Thursday amid reports that a body believed to be that of a 14-year-old boy was found this week near a Hells Angels hideout near Quebec City.

Since she was a young girl growing up in Vancouver, Ginny Lam says her mom Yat Hei Law made it very clear she favoured her son William, because he was her male heir.

An Ontario man says it is 'unfair' to pay a $1,500 insurance surcharge because his four-year-old SUV is at a higher risk of being stolen.

For the last seven-and-half months, Toronto resident Heather McArthur has been living out what she describes as her 'worst nightmare.' On Feb. 7, her then three-year-old son Jacob along with his father Loc Phu 'Jay' Le departed for what was supposed to be a week-long visit to Vietnam to celebrate the Lunar New Year with family, McArthur says.

Local Spotlight

They say a dog is a man’s best friend. In the case of Darren Cropper, from Bonfield, Ont., his three-year-old Siberian husky and golden retriever mix named Bear literally saved his life.

A growing group of brides and wedding photographers from across the province say they have been taken for tens of thousands of dollars by a Barrie, Ont. wedding photographer.

Paleontologists from the Royal B.C. Museum have uncovered "a trove of extraordinary fossils" high in the mountains of northern B.C., the museum announced Thursday.

The search for a missing ancient 28-year-old chocolate donkey ended with a tragic discovery Wednesday.

The Royal Canadian Mounted Police is celebrating an important milestone in the organization's history: 50 years since the first women joined the force.

It's been a whirlwind of joyful events for a northern Ontario couple who just welcomed a baby into their family and won the $70 million Lotto Max jackpot last month.

A Good Samaritan in New Brunswick has replaced a man's stolen bottle cart so he can continue to collect cans and bottles in his Moncton neighbourhood.

David Krumholtz, known for roles like Bernard the Elf in The Santa Clause and physicist Isidor Rabi in Oppenheimer, has spent the latter part of his summer filming horror flick Altar in Winnipeg. He says Winnipeg is the most movie-savvy town he's ever been in.

Edmontonians can count themselves lucky to ever see one tiger salamander, let alone the thousands one local woman says recently descended on her childhood home.

Stay Connected